Antifracture efficacy of strontium ranelate in postmenopausal osteoporosis

Bone

Volumn 40, Issue 5 SUPPL., 2007, Pages

  Roux, Christian ^a  

^a Rheumatology Department ^*  (France)

Author keywords

Antifracture efficacy; Nonvertebral fracture; Osteoporosis; Strontium ranelate; Vertebral fracture

Indexed keywords

ALKALINE PHOSPHATASE; PLACEBO; STRONTIUM RANELATE;

AGE; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; ECZEMA; FAMILY HISTORY; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP FRACTURE; HUMAN; MEDICAL DECISION MAKING; NAUSEA; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 34147101147     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.02.005     Document Type: Article

References (4)

1. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350 (2004) 459-468
2. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90 (2005) 2816-2822
3. Roux C., Reginster J.Y., Fechtenbaum J., Kolta S., Sawicki A., Tulassay Z., et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J. Bone Miner. Res. 21 (2006) 536-542
4. Seeman E., Vellas B., Benhamou C., Aquino J.P., Semler J., Kaufman J.M., et al. Strontium ranelate reduces the risk of vertebral and non vertebral fractures in women eighty years of age and older. J. Bone Miner. Res. 21 (2006) 1113-1120